- Remdesivir is an experimental antiviral drug made by the company Gilead. Designed to act against the RNA driven RNA polymerase enzyme in RNA viruses, it was initially tested on Ebola.
- Since coronaviruses are also RNA viruses, Remdesivir is expected to work on them, too.
- Published in The Lancet: Clinical trial of remdesivir in adults with severe COVID-19
- Randomized, double-blinded
- 237 patients
- Placebo controlled
- Multi-center
- 10 hospitals in China
- Bottom line
- Any improvement was not statistically significant
- Randomized, double-blinded
Category: News
-
Remdesivir Hopes
-
Migration to Volleysensei.com
The Volleysensei content will now live under it’s own domain at VolleySensei.com. To everyone who is subscribed to the blog and are primarily interested in the volleyball related content, please subscribe there.
Thank you.